Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740890 · ClinicalTrials.gov registry record · Phase 4
Exercise and Olanzapine-samidorphan
A Phase 4 study of Schizoaffective Disorder and Schizophenia Disorder, sponsored by New York State Psychiatric Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06740890 is a Phase 4 study of Schizoaffective Disorder and Schizophenia Disorder that is actively recruiting participants, run by New York State Psychiatric Institute. The registered enrollment target is 30 participants, below the 201-participant average among 81 other Schizoaffective Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06740890, a Phase 4 study of Schizoaffective Disorder and Schizophenia Disorder, is actively recruiting participants, sponsored by New York State Psychiatric Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.
Conditions Studied
Interventions
- DRUG Olanzapine-samidorphan + exercise
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06740890
The ClinicalTrials.gov registry entry for NCT06740890 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 81 other Schizoaffective Disorder trials with a reported enrollment target (85% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Schizoaffective Disorder appearing as the primary indexed condition, and to 1 intervention - of which Olanzapine-samidorphan + exercise is the first listed.
NCT06740890 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06740890 about?
NCT06740890 is a clinical study titled "Exercise and Olanzapine-samidorphan". This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.
What is the current status of trial NCT06740890?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-06-26. Estimated completion is 2027-04.
What conditions does trial NCT06740890 study?
This clinical trial studies the following conditions: Schizoaffective Disorder, Schizophenia Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS.
What interventions are being tested in trial NCT06740890?
The interventions under investigation include: Olanzapine-samidorphan + exercise (DRUG).
Who is sponsoring clinical trial NCT06740890?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740890 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizoaffective Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anticholinergic Deprescription in Schizophrenia
RECRUITING · Phase 4
-
Prebiotic Treatment in People With Schizophrenia - Pilot Study
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.